Abstract
Background
Nebivolol is a novel, β1‐adrenergic receptor blocker with vasodilatory properties mediated through activation of the L‐arginine/nitric oxide pathway.
Hypothesis
This multicenter, double‐blind, parallel‐group, placebo‐controlled study investigated the antihypertensive efficacy and safety of nebivolol in patients with stage I through stage II hypertension (sitting diastolic blood pressure [SiDBP] ≥ 95 mm Hg and ≤ 109 mm Hg).
Methods
A total of 811 patients were randomized to placebo or nebivolol 5 mg, 10 mg, or 20 mg once daily for 12 weeks. The primary efficacy endpoint was the reduction in mean trough SiDBP from baseline.
Results
At study end, the least squares mean reductions in trough SiDBP from baseline with nebivolol 5 mg, 10 mg, and 20 mg were − 7.8 mm Hg, − 8.5 mm Hg, and − 9.1 mm Hg, respectively, compared with − 4.6 mm Hg for placebo (P = .002 for nebivolol 5 mg, P<.001 for nebivolol 10 mg and 20 mg, vs placebo). Nebivolol treatment also produced reductions in trough sitting systolic blood pressure; however, only the 20 mg dose was statistically significant compared with placebo (−6.7 mm Hg vs − 0.4 mm Hg; P<.001). Response rates (defined as an average trough SiDBP < 90 mm Hg or a decrease by ≥ 10 mm Hg from baseline at the end of the study) ranged from 66.0% to 68.9% with nebivolol 5–20 mg, compared with 49.3% with placebo (P≤.009). Nebivolol 5 mg and 10 mg doses were well tolerated, with an overall adverse event incidence comparable to placebo.
Conclusions
Once‐daily nebivolol is an effective antihypertensive agent in patients with stage I‐II hypertension. Copyright © 2010 Wiley Periodicals, Inc.
Keywords: nebivolol, β‐blockers, hypertension, tolerability, nitric oxide
Full Text
The Full Text of this article is available as a PDF (507.4 KB).
References
- 1. Prichard BN, Cruickshank JM, Graham BR. Beta‐adrenergic blocking drugs in the treatment of hypertension. Blood Press. 2001; 10(5–6): 366–386. [DOI] [PubMed] [Google Scholar]
- 2. Weber MA. The role of the new beta‐blockers in treating cardiovascular disease. Am J Hypertens. 2005; 18(12 pt 2): 169S–176S. [DOI] [PubMed] [Google Scholar]
- 3. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004; 292(18): 2227–2236. [DOI] [PubMed] [Google Scholar]
- 4. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol. 2003; 92(3): 344–348. [DOI] [PubMed] [Google Scholar]
- 5. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res. 1998; 38(6): 419–431. [DOI] [PubMed] [Google Scholar]
- 6. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs. 1999; 57(4): 633–651. [DOI] [PubMed] [Google Scholar]
- 7. Weiss RJ, Weber MA, Carr AA, Sullivan WA. A randomized, double‐blind, placebo‐controlled parallel‐group study to assess the efficacy and safety of nebivolol, a novel beta‐blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich). 2007; 9(9): 667–676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007; 9(11): 866–875. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Gradman A. Safety and tolerability of nebivolol: a pooled safety analysis comparing typical β‐blocker associated adverse events with placebo. J Clin Hypertens (Greenwich). 2008; 10(5 suppl A): A120–Y. [Google Scholar]
- 10. Grassi G, Trevano FQ, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild‐to‐moderate essential hypertension: results of a double‐blind randomized multicentre trial. Blood Press Suppl. 2003; 2: 35–40. [PubMed] [Google Scholar]
- 11. Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens. 2006; 8(suppl 4): 40–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Cockcroft JR. Exploring vascular benefits of endothelium‐derived nitric oxide. Am J Hypertens. 2005; 18(12 Pt 2): 177S–183S. [DOI] [PubMed] [Google Scholar]
- 13. Dawes M, Brett SE, Chowienczyk PJ, Mant TGK, Ritter JM. The vasodilatory action of nebivolol in forearm vasculature of subjects with essential hypertension. Br J Clin Pharmacol. 1999; 48: 460–463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L‐arginine/ NO‐dependent mechanism. J Pharmacol Exper Therapeut. 1995; 274: 1067–1071. [PubMed] [Google Scholar]
- 15. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension. A randomized, double‐blind crossover study. Circulation. 2001; 104: 511–514. [DOI] [PubMed] [Google Scholar]
- 16. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double‐blind randomised trial. J Hum Hypertens. 1997; 11(12): 813–819. [DOI] [PubMed] [Google Scholar]
- 17. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double‐blind randomised trial. J Hum Hypertens. 1998; 12(2): 135–140. [DOI] [PubMed] [Google Scholar]